References
- AusCVDRisk. How the calculator was developed. At: www.cvdcheck.org.au/how-the-calculator-was-developed
- Heart Foundation. Game-changing new approach to stopping cardiovascular disease before it strikes. 2023. At: www.heartfoundation.org.au/media-releases/new-approach-prevention-of-cardiovascular-disease
- Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. 2024. At: www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/disease-types#deaths-trends
- Brown S, Banks E, Woodward M et al. Evidence supporting the choice of a new cardiovascular risk equation for Australia. Med J Aust. 2023 26;219(4):173—186.
- Heart Foundation. Key statistics: cardiovascular disease. 2024. At: www.heartfoundation.org.au/your-heart/evidence-and-statistics/key-stats-cardiovascular-disease
- Lincoff MA, Brown-Fransden K, Calhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 389;24.
- Queensland Health. Queensland community pharmacy pilots. 2024. At: www.health.qld.gov.au/clinical-practice/guidelines-procedures/community-pharmacy-pilots/about
- Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024;404(10454):773–86.
- Lincoff MA, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Eng J Med 2023;389(24):2221–32.
- US Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. 2024. At: www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- Victor Chang Cardiac Research Institute. Weight loss drugs a vital new tool in preventing heart attacks. 2024. At: www.victorchang.edu.au/news/ozempic